Literature DB >> 26005835

RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.

Philippe Depeille1, Linda M Henricks1, Robert A H van de Ven1, Ed Lemmens1, Chih-Yang Wang2, Mary Matli3, Zena Werb1, Kevin M Haigis4, David Donner3, Robert Warren3, Jeroen P Roose1.   

Abstract

The character of EGFR signals can influence cell fate but mechanistic insights into intestinal EGFR-Ras signalling are limited. Here we show that two distinct Ras nucleotide exchange factors, RasGRP1 and SOS1, lie downstream of EGFR but act in functional opposition. RasGRP1 is expressed in intestinal crypts where it restricts epithelial growth. High RasGRP1 expression in colorectal cancer (CRC) patient samples correlates with a better clinical outcome. Biochemically, we find that RasGRP1 creates a negative feedback loop that limits proliferative EGFR-SOS1-Ras signals in CRC cells. Genetic Rasgrp1 depletion from mice with either an activating mutation in KRas or with aberrant Wnt signalling due to a mutation in Apc resulted in both cases in exacerbated Ras-ERK signalling and cell proliferation. The unexpected opposing cell biological effects of EGFR-RasGRP1 and EGFR-SOS1 signals in the same cell shed light on the intricacy of EGFR-Ras signalling in normal epithelium and carcinoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26005835      PMCID: PMC4652934          DOI: 10.1038/ncb3175

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  69 in total

1.  Mutant KRAS promotes hyperplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool.

Authors:  Ying Feng; Guido T Bommer; Jenny Zhao; Maranne Green; Evan Sands; Yali Zhai; Kelly Brown; Aaron Burberry; Kathleen R Cho; Eric R Fearon
Journal:  Gastroenterology       Date:  2011-05-18       Impact factor: 22.682

2.  Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype.

Authors:  D W Threadgill; A A Dlugosz; L A Hansen; T Tennenbaum; U Lichti; D Yee; C LaMantia; T Mourton; K Herrup; R C Harris
Journal:  Science       Date:  1995-07-14       Impact factor: 47.728

3.  Unusual interplay of two types of Ras activators, RasGRP and SOS, establishes sensitive and robust Ras activation in lymphocytes.

Authors:  Jeroen P Roose; Marianne Mollenauer; Mary Ho; Tomohiro Kurosaki; Arthur Weiss
Journal:  Mol Cell Biol       Date:  2007-02-05       Impact factor: 4.272

4.  Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium.

Authors:  Daekee Lee; Ming Yu; Eunjung Lee; Hyunok Kim; Yanan Yang; Kyoungmi Kim; Christina Pannicia; Jonathan M Kurie; David W Threadgill
Journal:  J Clin Invest       Date:  2009-08-17       Impact factor: 14.808

5.  RasGRP Ras guanine nucleotide exchange factors in cancer.

Authors:  Olga Ksionda; Andre Limnander; Jeroen P Roose
Journal:  Front Biol (Beijing)       Date:  2013-10-01

6.  Autophosphorylation sites on the epidermal growth factor receptor.

Authors:  J Downward; P Parker; M D Waterfield
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

Review 7.  Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

Authors:  C J Marshall
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

8.  Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling.

Authors:  Vivian W Y Wong; Daniel E Stange; Mahalia E Page; Simon Buczacki; Agnieszka Wabik; Satoshi Itami; Marc van de Wetering; Richard Poulsom; Nicholas A Wright; Matthew W B Trotter; Fiona M Watt; Doug J Winton; Hans Clevers; Kim B Jensen
Journal:  Nat Cell Biol       Date:  2012-03-04       Impact factor: 28.824

9.  An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types.

Authors:  Eike Staub; Joern Groene; Maya Heinze; Detlev Mennerich; Stefan Roepcke; Irina Klaman; Bernd Hinzmann; Esmeralda Castanos-Velez; Christian Pilarsky; Benno Mann; Thomas Brümmendorf; Birgit Weber; Heinz-Johannes Buhr; André Rosenthal
Journal:  J Mol Med (Berl)       Date:  2009-04-28       Impact factor: 4.599

10.  Rasgrp1 mutation increases naive T-cell CD44 expression and drives mTOR-dependent accumulation of Helios⁺ T cells and autoantibodies.

Authors:  Stephen R Daley; Kristen M Coakley; Daniel Y Hu; Katrina L Randall; Craig N Jenne; Andre Limnander; Darienne R Myers; Noelle K Polakos; Anselm Enders; Carla Roots; Bhavani Balakishnan; Lisa A Miosge; Geoff Sjollema; Edward M Bertram; Matthew A Field; Yunli Shao; T Daniel Andrews; Belinda Whittle; S Whitney Barnes; John R Walker; Jason G Cyster; Christopher C Goodnow; Jeroen P Roose
Journal:  Elife       Date:  2013-12-12       Impact factor: 8.140

View more
  26 in total

1.  Flavors of EGFR-Ras signals impacting intestinal homeostasis.

Authors:  Philippe Depeille; Jeroen P Roose
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.

Authors:  Oghenekevwe M Gbenedio; Caroline Bonnans; Delphine Grun; Chih-Yang Wang; Ace J Hatch; Michelle R Mahoney; David Barras; Mary Matli; Yi Miao; K Christopher Garcia; Sabine Tejpar; Mauro Delorenzi; Alan P Venook; Andrew B Nixon; Robert S Warren; Jeroen P Roose; Philippe Depeille
Journal:  JCI Insight       Date:  2019-06-25

3.  Regulation of the Small GTPase Ras and Its Relevance to Human Disease.

Authors:  Kayla R Kulhanek; Jeroen P Roose; Ignacio Rubio
Journal:  Methods Mol Biol       Date:  2021

4.  Differential Role of the RasGEFs Sos1 and Sos2 in Mouse Skin Homeostasis and Carcinogenesis.

Authors:  Pilar Liceras-Boillos; David Jimeno; Rósula García-Navas; L Francisco Lorenzo-Martín; Mauricio Menacho-Marquez; Carmen Segrelles; Carmela Gómez; Nuria Calzada; Rocío Fuentes-Mateos; Jesús M Paramio; Xosé R Bustelo; Fernando C Baltanás; Eugenio Santos
Journal:  Mol Cell Biol       Date:  2018-07-30       Impact factor: 4.272

5.  Orphan Gpr182 suppresses ERK-mediated intestinal proliferation during regeneration and adenoma formation.

Authors:  Daniel O Kechele; R Eric Blue; Bailey Zwarycz; Scott T Espenschied; Amanda T Mah; Marni B Siegel; Charles M Perou; Shengli Ding; Scott T Magness; P Kay Lund; Kathleen M Caron
Journal:  J Clin Invest       Date:  2017-01-17       Impact factor: 14.808

6.  Macrophage-Derived mir-155-Containing Exosomes Suppress Fibroblast Proliferation and Promote Fibroblast Inflammation during Cardiac Injury.

Authors:  Chunxiao Wang; Congcong Zhang; Luxin Liu; Xi A; Boya Chen; Yulin Li; Jie Du
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

7.  Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer.

Authors:  Max Hardy-Werbin; Pedro Rocha; Oriol Arpi; Álvaro Taus; Lara Nonell; Xavier Durán; Xavier Villanueva; Deborah Joseph-Pietras; Luke Nolan; Sarah Danson; Richard Griffiths; Miguel Lopez-Botet; Ana Rovira; Joan Albanell; Christian Ottensmeier; Edurne Arriola
Journal:  Oncoimmunology       Date:  2019-03-27       Impact factor: 8.110

8.  Gene expression in triple-negative breast cancer in relation to survival.

Authors:  Shuyang Wang; Alicia Beeghly-Fadiel; Qiuyin Cai; Hui Cai; Xingyi Guo; Liang Shi; Jie Wu; Fei Ye; Qingchao Qiu; Ying Zheng; Wei Zheng; Ping-Ping Bao; Xiao-Ou Shu
Journal:  Breast Cancer Res Treat       Date:  2018-05-10       Impact factor: 4.872

9.  RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics.

Authors:  Elisabeth Salzer; Deniz Cagdas; Miroslav Hons; Emily M Mace; Wojciech Garncarz; Özlem Yüce Petronczki; René Platzer; Laurène Pfajfer; Ivan Bilic; Sol A Ban; Katharina L Willmann; Malini Mukherjee; Verena Supper; Hsiang Ting Hsu; Pinaki P Banerjee; Papiya Sinha; Fabienne McClanahan; Gerhard J Zlabinger; Winfried F Pickl; John G Gribben; Hannes Stockinger; Keiryn L Bennett; Johannes B Huppa; Loïc Dupré; Özden Sanal; Ulrich Jäger; Michael Sixt; Ilhan Tezcan; Jordan S Orange; Kaan Boztug
Journal:  Nat Immunol       Date:  2016-10-24       Impact factor: 25.606

10.  Unexpected insights for anti-EGFR cancer therapy.

Authors:  Philippe Depeille; Robert S Warren; Jeroen P Roose
Journal:  Oncotarget       Date:  2015-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.